Theranica’s Nerivio Wearable Device Receives CE Mark for Acute Treatment of Migraine in Europe

 Theranica’s Nerivio Wearable Device Receives CE Mark for Acute Treatment of Migraine in Europe

Theranica’s Nerivio Wearable Device Receives CE Mark for Acute Treatment of Migraine in the Europe

Shots:

  • The CE mark is granted under the new MDR European regulation, allowing the wearable therapeutic device to be marketed in selected EU countries, starting in 2021
  • Nerivio has also received the US FDA’s approval for use in the acute treatment of migraine and is currently under review for chronic migraine. Nerivio is the first smartphone-controlled wearable device, connected with an app that keeps tracks of migraine episodes and provides analytics that a patient can share with their doctor, to help monitor and tailor treatment
  • Nerivio is a wireless remote electrical neuromodulation device for the acute treatment of migraine with/out aura in patients ≥18yrs. who do not have chronic migraine. The device is self-applied to the upper-arm and should be used in the home environment at the onset of migraine headache or aura

Click here ­to­ read full press release/ article | Ref: Theranica | Image: Theranica

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post